ClinicalTrials.gg
CompletedNCT06215859Updated Feb 10, 2026

Study of MR-107A-02 for the Treatment of Acute Postoperative Pain Following Herniorrhaphy

A Phase 3 interventional study of MR-107A-02 and Tramadol in Acute Pain, Post Operative Pain and Pain, sponsored by Viatris Specialty LLC. Completed at 18 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-10.

Sponsored by Viatris Specialty LLC (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Jan 2025, 1 year 9 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Jan 2026.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
579
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 353 studies in Acute Pain with a site in United States — 49 open to participants now, 55 under way, 1 of them phase 3. Acute Pain · United States.

Enrollment
19th of 322
579 · median 86
Started
2023
with 21 others
Phase 3
42 of 353
1 open now
Registered
297th of 353
by date

Among the 353 studies in Acute Pain with a site in United States, this one is the 19th largest by enrollment of the 322 interventional ones that give a count, is one of 22 that started in 2023, is one of 42 in phase 3, and was the 297th registered.

Acute Pain

1,077 studies on the registry are indexed under Acute Pain; 168 are open to participants now.

Browse Acute Pain studies →

Open to participants now

49 of the 353 studies in Acute Pain with a site in United States are open now. Recruiting first, the newest first:

44 more — sign in →

All 49 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 353 studies in Acute Pain with a site in United States, or all of them as a file.
02

Study summary

MR-107A-02 is being studied to investigate its efficacy and safety for treatment of acute pain after herniorrhaphy.

03

Conditions studied

  • Acute Pain
  • Post Operative Pain
  • Pain

Keywords

  • Pain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

1. Requirement for unilateral open inguinal herniorrhaphy with mesh under general anesthesia.

3. Has an Physical Status of I, II, or III.

4. Pain Intensity (PI) using NRS-R ≥4 at any given timepoint during the 5 hours following end of surgery in the eligibility assessment as well as in the baseline assessment (NRS-R and NRS-A) immediately pre-dosing.

5. Rating of moderate or severe pain on a 4-point categorical pain rating scale (i.e., none, mild, moderate, severe) during the 5 hours following end of surgery.

6. Able to understand and complete the study requirements (including literacy, to enable diary and questionnaire completion), provide written , and agree to abide by the study protocol and its restrictions.

Main Exclusion Criteria:

  1. Previously dosed with this formulation of MR 107A 02.
  2. Had any prior inguinal hernia repair in the past 24 months.
  3. Has a planned concurrent surgical procedure (e.g., bilateral herniorrhaphy).
  4. Has a pre-existing concurrent acute or chronic painful physical/restrictive condition expected to require analgesic treatment in the postoperative period for pain that is not strictly related to the herniorrhaphy, and which may confound the postoperative assessments.
  5. Known to aspirin, NSAIDs, or other medication used in the study.
  6. (BMI) >40 kg/m2 at screening.
  7. Body weight of \<43 kg (105.8 lbs) at screening.
  8. History of GI bleeding or peptic ulcer disease.
  9. Known active inflammatory bowel disease, e.g., Crohn's Disease or ulcerative colitis.
  10. A history of bleeding disorders that may affect coagulation.
  11. Subjects with prior stroke or in the past 12 months prior to screening.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
579 participants (actual)

Study arms

  • Experimental
    MR-107A-02

    15 mg Twice daily (BID) during in patient phase (0-48 hours following randomization) 15 mg BID dosing morning and evening, during out patient phase (5 days) .

    Drug: MR-107A-02 · Procedure: Herniorrhaphy

  • Active comparator
    Tramadol

    50 mg, administered every 6 hours (q6h) during the in patient phase (0-48 hours following randomization). Placebo will be administered during out patient phase.

    Drug: Tramadol · Drug: Placebo · Procedure: Herniorrhaphy

  • Placebo comparator
    Placebo

    Placebo is administered every 6 hours (q6h) during the in patient phase (0-48 hours following randomization) and twice daily during the out patient phase.

    Drug: Placebo · Procedure: Herniorrhaphy

Interventions

  • tablet

  • over-encapsulated tablet

  • DrugPlacebo

    over-encapsulated tablet and/or tablet

  • ProcedureHerniorrhaphy

    Unilateral open inguinal herniorrhaphy with mesh under general anesthesia

06

What researchers measure

Primary outcomes

  1. Summed Pain Intensity Difference (SPID) for MR-107A-02 versus placebo.

    SPID based on a 0 to 10-point numeric rating scale with activity (NRS-A) for MR-107A-02 versus placebo.

    Time frame: 48 hours after randomization

Secondary outcomes

  1. Number of doses of opioid rescue medication taken for MR-107A-02 versus placebo.

    Number of doses of opioid rescue medication over the combined in-patient and outpatient treatment phases MR-107A-02 versus placebo.

    Time frame: 7 days after randomization

  2. Proportion of subjects using no opioid rescue medication MR-107A-02 versus placebo.

    Proportion of subjects using no opioid rescue medication over the combined in-patient and outpatient treatment phases MR-107A-02 versus placebo.

    Time frame: 7 days after randomization

  3. Summed Pain Intensity Difference (SPID) for tramadol versus placebo.

    SPID based on a 0 to 10-point numeric rating scale with activity (NRS-A) for tramadol versus placebo.

    Time frame: 7 days after randomization

  4. Summed Pain Intensity Difference (SPID) for MR-107A-02 versus tramadol

    SPID based on a 0 to 10-point numeric rating scale with activity (NRS-A) for MR-107A-02 versus tramadol.

    Time frame: 48 hours after randomization

07

Study locations

18 sites
  • Investigator site 210
    Sheffield, Alabama 35660, United States
  • Investigator site 213
    Phoenix, Arizona 85053, United States
  • Investigator site 202
    Anaheim, California 92801, United States
  • Investigator site 222
    Bakersfield, California 93301, United States
  • Investigator site 208
    Riverside, California 92501, United States
  • Investigator site 211
    Miami, Florida 33014, United States
  • Investigator site 206
    Tampa, Florida 33613, United States
  • Investigator site 207
    Atlanta, Georgia 30331, United States
  • Investigator site 205
    Wichita, Kansas 67214, United States
  • Investigator site 212
    Bellaire, Texas 77401, United States
  • Investigator site 215
    Carrollton, Texas 75006, United States
  • Investigator site 204
    Houston, Texas 77008, United States
  • Investigator site 216
    McAllen, Texas 78501, United States
  • Investigator site 219
    San Antonio, Texas 78229, United States
  • Investigator site 203
    San Antonio, Texas 78240, United States
  • Investigator site 214
    San Antonio, Texas 78258, United States
  • Investigator site 201
    Salt Lake City, Utah 84107, United States
  • Investigator site 224
    Eau Claire, Wisconsin 54701, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2023 to primary completion in Jan 2025, 13 months.

Of 29 industry-sponsored phase 3 interventional studies under Acute Pain, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's 13 months is above that.

Counting every sponsor, half of 54 studies reached it within 14 months; a quarter within 7 and three quarters within 25.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2023
First posted
Jan 22, 2024
StartActual
Dec 29, 2023
Primary completionActual
Jan 31, 2025
CompletionActual
Mar 12, 2025
Results delay requested
Jan 22, 2026
Last update
Feb 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06215859
Collaborators
Mylan Specialty, LP
Responsible party
Sponsor
First posted
Jan 22, 2024
Start date
Dec 29, 2023
Primary completion
Jan 31, 2025
Completion
Mar 12, 2025
Last update
Feb 10, 2026

Study contacts

Susanne Vogt
study director · Viatris Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MR-107A-02

Start the discussion